BUSINESS
    Takeda Aims for Mid-Teens Annual Growth in Japan Oncology Biz: Exec
    March 8, 2021
    With a string of new cancer drugs and indications coming along in its pipeline, Takeda Pharmaceutical is targeting a compound annual growth rate in the mid-teens, or at least double-digit growth, over the next five…

    LATEST

    Imfinzi, 2 Other Drugs under PMDA Safety Review
    March 8, 2021
    The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating a new side effect risk for three drugs including AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab), a move likely to trigger label changes in the near future.According to the agency’s risk communication update…
    Viatris Rolls Out 3 Follow-On AGs for Norvasc, Cardenalin, Relpax
    March 8, 2021
    Viatris Pharmaceuticals Japan said on March 5 that authorized generic (AG) versions are now available for the hypertension treatments Norvasc (amlodipine) and Cardenalin (doxazosin mesilate) and the migraine drug Relpax (eletriptan).Amlodipine Tablets/OD Tablets “Pfizer”, Doxazosin Tablets “Pfizer”, and Eletriptan Tablets…
    Japan Ethical Drug Sales Down 5.3% in January: Crecon
    March 8, 2021
    Japan’s ethical drug sales dropped 5.3% in January over the same month the previous year on a wholesaler shipment basis, according to a flash report released by Crecon Research & Consulting. The reporting month had the same number of business…

    COMMENTARY

    Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest
    By Takashi Ohama

    The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…

    INTERVIEW

    From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
    By Yoshinori Sagehashi

    Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

    FY2020 Drug Pricing Reform

    Japan Panel Hammers Out FY2020 Drug Pricing Reform

    Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

    Reimbursement Listing in 2018-2019

    Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing

    The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    COLUMN

    What Personal Biases Influence Your Hires?
    By Philip Carrigan

    By managing personal bias during the interview process, hiring managers can significantly improve their hit rate placing winning candidates. The trouble is, it’s easier said than done. It’s only natural we tend to like people we can relate to, people…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA